This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
02/10/16 - 10:48:50 AM ET (BATS BZX Real-time Price)
GRFS Day's Range
GRFS 52 Week Range
GRFS Business Summary
Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes plasma derivative products in the United States, Canada, Spain, rest of the European Union, and internationally.View GRFS
Grifols SA - GRFS - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates Grifols SA as a
Buy with a ratings score of B-.
Report Snippet: We rate GRIFOLS SA (GRFS) a BUY. This is driven by some important positives, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, growth in earnings per share, increase in net income and expanding profit margins. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself.